Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer Schering Pharma wins industry honour for Xarelto

Bayer Schering Pharma wins industry honour for Xarelto

11th October 2010

Bayer Schering Pharma has been presented with a prestigious industry award for its venous thromboembolism (VTE) treatment Xarelto.

The company has earned the Prix Galien International 2010 for the rivaroxaban-based therapy in the category of best pharmaceutical agent, following deliberation by an awards committee that included several Nobel Laureates.

This award is considered to be the biopharmaceutical industry equivalent of the Nobel Prize, with Xarelto having already won national Prix Galien awards in France, Belgium and Switzerland.

Dr Marijn Dekkers, chairman of the board of management of Bayer, said the honour reflects the efficacy its drug has shown among patients undergoing total hip or knee replacement surgery.

He added: "Being awarded the International Prix Galien for best pharmaceutical agent underscores the drive for innovation that characterises the focus of our company and our continuing ambition to improve the quality of life of patients."

In August 2010, the company published data from a clinical trial of rivaroxaban, demonstrating its potential in treating VTE in patients with acute symptomatic deep vein thrombosis.ADNFCR-8000103-ID-800108377-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.